For US residents only.

Download Helpful Materials

Sandostatin® LAR Depot

Important Safety Information:

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.

Before taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common side effects: Most patients experience side effects at some time. Some common side effects you may experience include:

  • Acromegaly: diarrhea, gallstones, abdominal pain, and flatulence
  • Carcinoid tumors: back pain, fatigue, headache, abdominal pain, nausea, and dizziness

Other information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:

  • Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal)
  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.

Important Safety Information:

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring b

... See More
Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:

  • Long-term maintenance therapy in acromegalic pa
... See More

Know Your Numbers: Getting to Normal and Staying There

Clinical Nurse Specialist Daphne Adelman, RN, BSN, MBA, will walk you through the numbers to know when you’re living with acromegaly. Learn what's normal and what's not, and how to work with your doctor to help get your numbers in the normal range.

15:03
15:03

Help Manage Your GH and IGF-1 Levels, Make Smart Choices

Learn how to get active in monitoring and managing your acromegaly, and about healthy choices you can make every day, with your doctor’s approval.

16:54
16:54

Taking a Proactive Role in Your Acromegaly Care

What does it mean to be proactive? Clinical Nurse Specialist Daphne Adelman, RN, BSN, MBA, shows you how to take an active part in managing your acromegaly, including learning about the disease, knowing your numbers, following your doctor's advice, taking care of yourself, and living a healthy lifestyle.

Acromegaly Audio Chats: Episode 1

Listen to patients share their strategies for living with acromegaly. Hear their discussions about being diagnosed and gaining inspiration from other patients. While the patients in this group are portrayed by actors, the stories they share are based on real experiences of patients like you.

27:20
27:20

Encouragement and Support From Donna Wall

Listen to the perspective of a patient with acromegaly, Donna Wall, and find comfort and inspiration from her story. Hear how she maintains a sense of control over her life with acromegaly and encourages knowledge and support for both patients and caregivers.

16:41
16:41

Doctor Discussion Guide

Download talking tips and suggested questions to bring to your next doctor's appointment. Come prepared with questions from tracking your symptoms and treating your disease to talking confidently and openly about managing your acromegaly.

Support Groups

Your health care provider is your first source of information because he or she understands your individual medical needs. Still, the Internet can be a good source of information about acromegaly, and it provides a way for patients and families to talk with one another, and share feelings and resources. On this page, you will find links to sites that provide acromegaly resources and support groups.

 

Acromegaly Resources and Support Groups

 

The Pituitary Network Association (PNA)*
The Pituitary Network Association (PNA) is an international nonprofit organization for patients with pituitary tumors and disorders, their families, loved ones, and the physicians and health care providers who treat them.
http://www.pituitary.org or call 1-805-499-9973

 

The Neuroendocrine Clinical Center of Massachusetts General Hospital*
Harvard Medical School
http://pituitary.mgh.harvard.edu/

 

National Organization for Rare Disorders (NORD)*
NORD includes acromegaly in its rare-disease database and will e-mail or fax you a full report for a nominal fee.
http://www.rarediseases.org/ or call 1-800-999-NORD

 

The Hormone Foundation*
The Hormone Foundation is the public education affiliate of the Endocrine Society and is a leading source of hormone-related health information.
http://www.hormone.org

 

Acromegaly Community*
Acromegaly Community provides emotional and communal support for people touched by acromegaly.
http://acromegalycommunity.com/

 

*Novartis Pharmaceuticals Corporation may make donations to these support groups and organizations. However, Novartis Pharmaceuticals Corporation has no control over third-party websites and makes no representation as to the accuracy, completeness, adequacy, or any other aspects of the information contained on such websites.

Important Safety Information:

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.

Before taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common side effects: Most patients experience side effects at some time. Some common side effects you may experience include:

  • Acromegaly: diarrhea, gallstones, abdominal pain, and flatulence
  • Carcinoid tumors: back pain, fatigue, headache, abdominal pain, nausea, and dizziness

Other information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:

  • Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal)
  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.